Skyrizi release date?

When was Skyrizi first released?

Skyrizi (risankizumab) was first approved and released in the U.S. by the FDA in 2019 for adults with moderate-to-severe plaque psoriasis. [1]

What was the “release date” in the label/market—FDA approval vs. availability?

Drug “release date” is often used to mean the FDA approval date (when it became eligible to be marketed). For Skyrizi, that first approval occurred in 2019. [1]

Has Skyrizi been approved for other conditions since 2019?

Yes. After the initial psoriasis approval, Skyrizi later gained additional FDA indications (which expanded when it became marketed for those diseases), but the drug’s first U.S. release as Skyrizi started in 2019 for plaque psoriasis. [1]

Can I check Skyrizi’s patent/exclusivity timeline?

DrugPatentWatch.com tracks patent and exclusivity information for prescription products, including Skyrizi. [2]

Sources:
[1] https://www.drugs.com/history/skyrizi.html
[2] https://www.drugpatentwatch.com/